Suppr超能文献

预防性中央区颈部清扫术在甲状腺乳头状癌中的应用:全是风险,没有获益。

Prophylactic Central Neck Dissection in Papillary Thyroid Carcinoma: All Risks, No Reward.

机构信息

Department of Surgery, The University of Alabama at Birmingham, Birmingham, Alabama.

Department of Otolaryngology, The University of Alabama at Birmingham, Birmingham, Alabama.

出版信息

J Surg Res. 2021 Aug;264:230-235. doi: 10.1016/j.jss.2021.02.035. Epub 2021 Apr 8.

Abstract

BACKGROUND

Central neck dissection (CND) remains a controversial intervention for papillary thyroid carcinoma (PTC) patients with clinically negative nodes (cN0) in the central compartment. Proponents state that CND in cN0 patients prevents locoregional recurrence, while opponents deem that the risks of complications outweigh any potential benefit. Thus, there remains conflicting results amongst studies assessing oncologic and surgical outcomes in cN0 PTC patients who undergo CND. To provide clarity to this controversy, we sought to evaluate the efficacy, safety, and oncologic impact of CND in cN0 PTC patients at our institution.

MATERIALS AND METHODS

Six hundred and ninety-five patients with PTC who underwent thyroidectomy at our institution between 1998 and 2018 were identified using an institutional cancer registry and supplemental electronic medical record queries. Patients were stratified by whether or not they underwent CND; identified as CND(+) or CND(-), respectively. Patients were also stratified by whether or not they received adjuvant radioactive iodine (RAI) therapy. Patient demographics, pathologic results, as well as surgical and oncologic outcomes were reviewed. Standard statistical analyses were performed using ANOVA and/or t-test and chi-squared tests as appropriate.

RESULTS

Among the 695 patients with PTC, 492 (70.8%) had clinically and radiographically node negative disease (cN0). The mean age was 50 ± 1 years old and 368 (74.8%) were female. Of those with cN0 PTC, 61 patients (12.4%) underwent CND. CND(+) patients were found to have higher preoperative thyroid stimulating hormone (TSH) values, 2.8 ± 0.8 versus 1.5 ± 0.2 mU/L (P = 0.028) compared to CND(-) patients. CND did not significantly decrease disease recurrence, development of distant metastatic disease (P = 0.105) or persistence of disease (P = 0.069) at time of mean follow-up of 38 ± 3 months compared to CND(-) patients. However, surgical morbidity rates were significantly higher in CND(+) patients; including transient hypocalcemia (36.1% versus 14.4%; P < 0.001), transient recurrent laryngeal nerve (RLN) injury (19.7% vers us 7.0%; P < 0.001), and permanent RLN injury (3.3% versus 0.7%; P < 0.001).

CONCLUSIONS

The majority of patients at our institution with cN0 PTC did not undergo CND. This data suggests that CND was not associated with improvements in oncologic outcomes during the short-term follow-up period and led to increased postoperative morbidity. Therefore, we conclude that CND should not be routinely performed for patients with cN0 PTC.

摘要

背景

中央颈部清扫术(CND)对于临床淋巴结阴性(cN0)的甲状腺乳头状癌(PTC)患者仍然是一种有争议的干预措施。支持者认为,CND 可预防局部区域复发,而反对者则认为并发症的风险超过任何潜在的益处。因此,在评估接受 CND 的 cN0 PTC 患者的肿瘤学和手术结果的研究中,仍然存在相互矛盾的结果。为了解决这一争议,我们试图评估我们机构中 cN0 PTC 患者 CND 的疗效、安全性和肿瘤学影响。

材料和方法

使用机构癌症登记处和补充电子病历查询,在我们机构 1998 年至 2018 年间接受甲状腺切除术的 695 名 PTC 患者。患者根据是否接受 CND 进行分层;分别为 CND(+)或 CND(-)。患者还根据是否接受辅助放射性碘(RAI)治疗进行分层。回顾患者的人口统计学数据、病理结果以及手术和肿瘤学结果。使用 ANOVA 和/或 t 检验和卡方检验进行适当的标准统计分析。

结果

在 695 名 PTC 患者中,492 名(70.8%)临床和影像学淋巴结阴性(cN0)。平均年龄为 50±1 岁,368 名(74.8%)为女性。在 cN0 PTC 患者中,61 名(12.4%)接受了 CND。与 CND(-)患者相比,CND(+)患者的术前甲状腺刺激激素(TSH)值更高,分别为 2.8±0.8 与 1.5±0.2 mU/L(P=0.028)。与 CND(-)患者相比,CND 并未显著降低疾病复发、远处转移疾病(P=0.105)或疾病持续存在(P=0.069)的风险。然而,在平均 38±3 个月的随访期间,CND(+)患者的手术发病率明显更高;包括短暂性低钙血症(36.1%比 14.4%;P<0.001)、短暂性喉返神经(RLN)损伤(19.7%比 7.0%;P<0.001)和永久性 RLN 损伤(3.3%比 0.7%;P<0.001)。

结论

我们机构的大多数 cN0 PTC 患者未接受 CND。该数据表明,在短期随访期间,CND 并未改善肿瘤学结果,并导致术后发病率增加。因此,我们得出结论,CND 不应常规用于 cN0 PTC 患者。

相似文献

1
Prophylactic Central Neck Dissection in Papillary Thyroid Carcinoma: All Risks, No Reward.
J Surg Res. 2021 Aug;264:230-235. doi: 10.1016/j.jss.2021.02.035. Epub 2021 Apr 8.
3
Long-term outcomes of central neck dissection for cN0 papillary thyroid carcinoma.
Am J Otolaryngol. 2017 Sep-Oct;38(5):576-581. doi: 10.1016/j.amjoto.2017.06.004. Epub 2017 Jun 14.
4
Level VII is an important component of central neck dissection for papillary thyroid cancer.
Ann Surg Oncol. 2013 Jul;20(7):2261-5. doi: 10.1245/s10434-012-2833-1. Epub 2013 Jan 30.
5
Central neck dissection for papillary thyroid cancer.
Arch Otolaryngol Head Neck Surg. 2009 Nov;135(11):1092-7. doi: 10.1001/archoto.2009.158.
6
Comparison of prophylactic ipsilateral and bilateral central lymph node dissection in papillary thyroid carcinoma: a meta-analysis.
Braz J Otorhinolaryngol. 2023 Nov-Dec;89(6):101318. doi: 10.1016/j.bjorl.2023.101318. Epub 2023 Sep 4.
9
Local lymph node recurrence after central neck dissection in papillary thyroid cancers: A meta analysis.
Eur Ann Otorhinolaryngol Head Neck Dis. 2019 Nov;136(6):481-487. doi: 10.1016/j.anorl.2018.07.010. Epub 2019 Jun 10.

引用本文的文献

1
Safety enhancement of improved hydrodissection for microwave ablation in lymph node metastasis from papillary thyroid carcinoma: a comparative study.
Front Endocrinol (Lausanne). 2025 Jul 23;16:1594561. doi: 10.3389/fendo.2025.1594561. eCollection 2025.
4
Central Neck Dissection in Papillary Thyroid Carcinoma: Benefits and Doubts in the Era of Thyroid Lobectomy.
Biomedicines. 2024 Sep 25;12(10):2177. doi: 10.3390/biomedicines12102177.
5
Prediction Model of Cervical Lymph Node Metastasis in Papillary Thyroid Carcinoma.
Cancer Control. 2024 Jan-Dec;31:10732748241295347. doi: 10.1177/10732748241295347.
8
Nomogram to predict central lymph node metastasis in papillary thyroid carcinoma.
Clin Exp Metastasis. 2024 Oct;41(5):613-626. doi: 10.1007/s10585-024-10285-3. Epub 2024 Apr 3.
10
Predictive factors of lymph node metastasis in papillary thyroid cancer.
PLoS One. 2023 Nov 27;18(11):e0294594. doi: 10.1371/journal.pone.0294594. eCollection 2023.

本文引用的文献

1
Practice patterns for surgical management of low-risk papillary thyroid cancer from 2014 to 2019: A CESQIP analysis.
Am J Surg. 2021 Feb;221(2):448-454. doi: 10.1016/j.amjsurg.2020.07.032. Epub 2020 Aug 21.
2
Prophylactic central lymph node dissection informs the decision of radioactive iodine ablation in papillary thyroid cancer.
Am J Surg. 2021 May;221(5):886-892. doi: 10.1016/j.amjsurg.2020.08.012. Epub 2020 Aug 18.
4
Thyroid Cancer: Risk-Stratified Management and Individualized Therapy.
Clin Cancer Res. 2016 Oct 15;22(20):5012-5021. doi: 10.1158/1078-0432.CCR-16-0484.
5
Prophylactic Central Neck Dissection Might Not Be Necessary in Papillary Thyroid Carcinoma: Analysis of 11,569 Cases from a Single Institution.
J Am Coll Surg. 2016 May;222(5):853-64. doi: 10.1016/j.jamcollsurg.2016.02.001. Epub 2016 Feb 13.
6
Nodal metastases in thyroid cancer: prognostic implications and management.
Future Oncol. 2016 Apr;12(7):981-94. doi: 10.2217/fon.16.10. Epub 2016 Mar 7.
10
Controversies in primary treatment of low-risk papillary thyroid cancer.
Lancet. 2013 Mar 23;381(9871):1046-57. doi: 10.1016/S0140-6736(12)62205-3. Epub 2013 Mar 22.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验